Massimo Locati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8654248/publications.pdf

Version: 2024-02-01

197 papers 38,554 citations

13854 67 h-index 2894 190 g-index

202 all docs $\begin{array}{c} 202 \\ \\ \text{docs citations} \end{array}$

times ranked

202

46255 citing authors

#	Article	IF	CITATIONS
1	Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions. Journal of Leukocyte Biology, 2022, 111, 817-836.	1.5	23
2	Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections. Frontiers in Pharmacology, 2022, 13, 879020.	1.6	8
3	Endogenous modification of the chemoattractant CXCL5 alters receptor usage and enhances its activity toward neutrophils and monocytes. Science Signaling, 2021, 14 , .	1.6	8
4	The tetraspan MS4A family in homeostasis, immunity, and disease. Trends in Immunology, 2021, 42, 764-781.	2.9	33
5	Tumor-Released Products Promote Bone Marrow-Derived Macrophage Survival and Proliferation. Biomedicines, 2021, 9, 1387.	1.4	3
6	ERα-independent NRF2-mediated immunoregulatory activity of tamoxifen. Biomedicine and Pharmacotherapy, 2021, 144, 112274.	2.5	3
7	Immunotherapeutic early-phase clinical trials and malignant gliomas: a single-center experience and comprehensive immunophenotyping of circulating leukocytes. Neuro-Oncology Advances, 2021, 3, vdab160.	0.4	1
8	Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 123-147.	9.6	932
9	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology, 2020, 225, 151853.	0.8	50
10	\hat{l}^2 -Arrestin1 and \hat{l}^2 -Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4. Frontiers in Immunology, 2020, 11, 550824.	2.2	13
11	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 2020, 59, 102844.	2.7	41
12	Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia. International Journal of Molecular Sciences, 2020, 21, 5696.	1.8	11
13	Reciprocal interference between the NRF2 and LPS signaling pathways on the immuneâ€metabolic phenotype of peritoneal macrophages. Pharmacology Research and Perspectives, 2020, 8, e00638.	1.1	8
14	Control of Cytoskeletal Dynamics by \hat{l}^2 -Arrestin 1/Myosin Vb Signaling Regulates Endosomal Sorting and Scavenging Activity of the Atypical Chemokine Receptor ACKR2. Vaccines, 2020, 8, 542.	2.1	7
15	ACKR2 contributes to pulmonary dysfunction by shaping CCL5:CCR5-dependent recruitment of lymphocytes during influenza A infection in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L655-L670.	1.3	15
16	New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines, 2020, 8, 164.	2.1	9
17	Chemokine receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	1
18	Macrophage ferroportin is essential for stromal cell proliferation in wound healing. Haematologica, 2019, 104, 47-58.	1.7	42

#	Article	IF	CITATIONS
19	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasis. Nature Immunology, 2019, 20, 1012-1022.	7.0	75
20	MicroRNAs as Molecular Switches in Macrophage Activation. Frontiers in Immunology, 2019, 10, 799.	2.2	137
21	Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: A possible link to the cholinergic anti-inflammatory pathway. Journal of Neuroimmunology, 2019, 332, 155-166.	1.1	29
22	The Atypical Chemokine Receptor 2 Limits Progressive Fibrosis after Acute Ischemic Kidney Injury. American Journal of Pathology, 2019, 189, 231-247.	1.9	17
23	Chemokine receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
24	Chemokine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
25	The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis. Kidney International, 2018, 93, 826-841.	2.6	24
26	ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity. Nature Communications, 2018, 9, 676.	5.8	68
27	Mast Cell–Dependent CD8+ T-cell Recruitment Mediates Immune Surveillance of Intestinal Tumors in ApcMin/+ Mice. Cancer Immunology Research, 2018, 6, 332-347.	1.6	36
28	The elegance of a macrophage. Cellular and Molecular Immunology, 2018, 15, 196-198.	4.8	13
29	Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties. International Journal of Molecular Sciences, 2018, 19, 3768.	1.8	15
30	The estrogen–macrophage interplay in the homeostasis of the female reproductive tract. Human Reproduction Update, 2018, 24, 652-672.	5.2	32
31	Multi-Step Regulation of the TLR4 Pathway by the miR-125a~99b~let-7e Cluster. Frontiers in Immunology, 2018, 9, 2037.	2.2	40
32	Chemokines sound the alarmin: The role of atypical chemokine in inflammation and cancer. Seminars in Immunology, 2018, 38, 63-71.	2.7	35
33	Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu. Frontiers in Immunology, 2018, 9, 1823.	2.2	60
34	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2 ⁺ and CCR5 ⁺ FNγ-producing γÎT cells in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L1010-L1025.	1.3	32
35	Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy. Journal of Clinical Microbiology, 2017, 55, 1516-1525.	1.8	24
36	Atypical matters in myeloid differentiation. Nature Immunology, 2017, 18, 711-712.	7.0	3

#	Article	IF	CITATIONS
37	Self-renewal and phenotypic conversion are the main physiological responses of macrophages to the endogenous estrogen surge. Scientific Reports, 2017, 7, 44270.	1.6	58
38	Glucocorticoids downregulate TLR4 signaling activity via its direct targeting by miRâ€511â€5p. European Journal of Immunology, 2017, 47, 2080-2089.	1.6	33
39	Editorial: Regulation of Inflammation, Its Resolution and Therapeutic Targeting. Frontiers in Immunology, 2017, 8, 415.	2.2	12
40	Neutrophils in Gliomas. Frontiers in Immunology, 2017, 8, 1349.	2.2	101
41	The scavenging chemokine receptor ACKR2 has a significant impact on acute mortality rate and early lesion development after traumatic brain injury. PLoS ONE, 2017, 12, e0188305.	1.1	11
42	Analysis of G Protein and \hat{I}^2 -Arrestin Activation in Chemokine Receptors Signaling. Methods in Enzymology, 2016, 570, 421-440.	0.4	4
43	Allosteric Modulation of Chemoattractant Receptors. Frontiers in Immunology, 2016, 7, 170.	2.2	20
44	Cancer and Chemokines. Methods in Molecular Biology, 2016, 1393, 87-96.	0.4	25
45	Atypical Chemokine Receptors. , 2016, , 579-585.		0
46	Macrophage Metabolism Shapes Angiogenesis in Tumors. Cell Metabolism, 2016, 24, 653-654.	7.2	35
47	Flow Cytometry Detection of Chemokine Receptors for the Identification of Murine Monocyte and Neutrophil Subsets. Methods in Enzymology, 2016, 570, 441-456.	0.4	1
48	Atypical chemokine receptors in cancer: friends or foes?. Journal of Leukocyte Biology, 2016, 99, 927-933.	1.5	66
49	Overview and potential unifying themes of the atypical chemokine receptor family. Journal of Leukocyte Biology, 2016, 99, 883-892.	1.5	52
50	CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis. PLoS ONE, 2016, 11, e0166006.	1.1	39
51	MiR-146b Mediates Endotoxin Tolerance in Human Phagocytes. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	17
52	Chemokines as effector and target molecules in vascular biology. Cardiovascular Research, 2015, 107, 364-372.	1.8	30
53	An atypical addition to the chemokine receptor nomenclature: <scp>IUPHAR</scp> Review 15. British Journal of Pharmacology, 2015, 172, 3945-3949.	2.7	43
54	Phenotypic activation and pharmacological outcomes of spontaneously differentiated human monocyte-derived macrophages. Immunobiology, 2015, 220, 545-554.	0.8	75

#	Article	IF	CITATIONS
55	Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine. Gastroenterology, 2015, 149, 163-176.e20.	0.6	201
56	Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL- $1\hat{l}^2$, IFN- \hat{l}^2 , and IL-15 Pathways. Journal of Immunology, 2015, 195, 2818-2828.	0.4	90
57	Effect of shock waves on macrophages: A possible role in tissue regeneration and remodeling. International Journal of Surgery, 2015, 24, 124-130.	1.1	70
58	Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness. Oncolmmunology, 2014, 3, e955337.	2.1	6
59	Interplay of Inflammation, Immunity, and Organ-Specific Adiposity with Cardiovascular Risk. Mediators of Inflammation, 2014, 2014, 1-2.	1.4	0
60	Role of MicroRNA in Macrophage Activation and Polarization. , 2014, , 545-555.		1
61	Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16937-16942.	3.3	56
62	Flow cytometry applications for the analysis of chemokine receptor expression and function. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 292-301.	1.1	20
63	The Macrophage Transcriptome. , 2014, , 559-585.		1
64	ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma. Cancer Immunology Research, 2014, 2, 679-689.	1.6	33
65	International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacological Reviews, 2014, 66, 1-79.	7.1	735
66	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 339-340.	6.6	53
67	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 14-20.	6.6	4,638
68	Macrophages Have a Grip on the Gut. Immunity, 2014, 41, 11-13.	6.6	1
69	New nomenclature for atypical chemokine receptors. Nature Immunology, 2014, 15, 207-208.	7.0	176
70	Review: Structure–function and biological properties of the atypical chemokine receptor D6. Molecular Immunology, 2013, 55, 87-93.	1.0	9
71	Macrophage Activation and Polarization as an Adaptive Component of Innate Immunity. Advances in Immunology, 2013, 120, 163-184.	1.1	352
72	Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1478-1483.	1.1	232

#	Article	IF	CITATIONS
73	Dissecting Trafficking and Signaling of Atypical Chemokine Receptors. Methods in Enzymology, 2013, 521, 151-168.	0.4	3
74	Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood, 2013, 121, e57-e69.	0.6	426
75	Macrophage plasticity and polarization in tissue repair and remodelling. Journal of Pathology, 2013, 229, 176-185.	2.1	1,868
76	Regulation of the immune and inflammatory responses by the 'atypical' chemokine receptor <scp>D6</scp> . Journal of Pathology, 2013, 229, 168-175.	2.1	54
77	Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia, 2013, 27, 500-503.	3.3	67
78	î²-Arrestin–Dependent Activation of the Cofilin Pathway Is Required for the Scavenging Activity of the Atypical Chemokine Receptor D6. Science Signaling, 2013, 6, ra30.1-11, S1-3.	1.6	63
79	Atypical chemokine receptors: from silence to sound. Biochemical Society Transactions, 2013, 41, 231-236.	1.6	39
80	Negative regulation of Toll-like receptor 4 signaling by IL-10–dependent microRNA-146b. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11499-11504.	3.3	270
81	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clinical and Experimental Immunology, 2013, 173, 250-258.	1.1	109
82	Expression of the Atypical Chemokine Receptor D6 in Human Alveolar Macrophages in COPD. Chest, 2013, 143, 98-106.	0.4	36
83	The Chemokine Decoy Receptor D6 Prevents Excessive Inflammation and Adverse Ventricular Remodeling After Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2206-2213.	1.1	78
84	Semaphorin 4A Exerts a Proangiogenic Effect by Enhancing Vascular Endothelial Growth Factor-A Expression in Macrophages. Journal of Immunology, 2012, 188, 4081-4092.	0.4	64
85	Targeting Chemokines in Cancer. Current Immunology Reviews, 2012, 8, 161-169.	1.2	1
86	Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood, 2012, 119, 411-421.	0.6	292
87	Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. Blood, 2012, 119, 5250-5260.	0.6	33
88	Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. Autoimmunity Reviews, 2012, 11, 883-889.	2.5	109
89	IL-10–induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3101-10.	3.3	191
90	The biochemistry and biology of the atypical chemokine receptors. Immunology Letters, 2012, 145, 30-38.	1.1	145

#	Article	IF	Citations
91	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the \hat{I}^2 2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. Journal of Autoimmunity, 2012, 38, J209-J215.	3.0	58
92	Systemic and cellular consequences of macrophage control of iron metabolism. Seminars in Immunology, 2012, 24, 393-398.	2.7	37
93	Notch1 regulates chemotaxis and proliferation by controlling the CCâ \in chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. Journal of Pathology, 2012, 226, 713-722.	2.1	54
94	Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 nonâ€competitive allosteric inhibitor. British Journal of Pharmacology, 2012, 165, 436-454.	2.7	63
95	Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends in Immunology, 2011, 32, 241-247.	2.9	248
96	Novel Players in Female Fertility: The Long Pentraxin PTX3 and the Chemokine Decoy Receptor D6. Advances in Neuroimmune Biology, 2011, 2, 41-50.	0.7	1
97	Expression of the α7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. Journal of Neuroimmunology, 2011, 230, 74-84.	1.1	48
98	Chemokines and Cancer: A Fatal Attraction. Cancer Cell, 2011, 19, 434-435.	7.7	74
99	The Yin Yang of Cancer Related Inflammation. , 2011, , 11-16.		2
100	Control of iron homeostasis as a key component of macrophage polarization. Haematologica, 2010, 95, 1801-1803.	1.7	42
101	Chemokine receptors intracellular trafficking. , 2010, 127, 1-8.		77
102	Differential regulation of iron homeostasis during human macrophage polarized activation. European Journal of Immunology, 2010, 40, 824-835.	1.6	337
103	Convergent pathways of macrophage polarization: The role of B cells. European Journal of Immunology, 2010, 40, 2131-2133.	1.6	22
104	The Italian Society of Immunology: past, present and future. European Journal of Immunology, 2010, 40, 2664-2666.	1.6	1
105	Chemokine System: New Inflammatory Markers on the Horizon. European Journal of Inflammation, 2010, 8, 1-6.	0.2	7
106	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus, 2010, 19, 453-456.	0.8	53
107	Chemokine Decoy Receptors: Structure–Function and Biological Properties. Current Topics in Microbiology and Immunology, 2010, 341, 15-36.	0.7	44
108	The chemokine system in cancer biology and therapy. Cytokine and Growth Factor Reviews, 2010, 21, 27-39.	3.2	343

#	Article	IF	Citations
109	The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut, 2010, 59, 197-206.	6.1	138
110	Phosphoinositide 3-kinase \hat{I}^3 plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice. Journal of Leukocyte Biology, 2010, 89, 269-282.	1.5	61
111	Chemokines and chemokine receptors: an overview. Frontiers in Bioscience - Landmark, 2009, Volume, 540.	3.0	215
112	Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5282-5287.	3.3	515
113	Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence. Journal of Biological Chemistry, 2009, 284, 26207-26215.	1.6	49
114	Chapter 11 Role of the Chemokine Scavenger Receptor D6 in Balancing Inflammation and Immune Activation. Methods in Enzymology, 2009, 460, 231-243.	0.4	9
115	Synergistic upâ€regulation of MCPâ€2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and antiâ€tumoral effects. European Journal of Immunology, 2009, 39, 843-857.	1.6	57
116	Never Underestimate the Power of a Neutrophil. Immunity, 2009, 31, 698-700.	6.6	44
117	Macrophage Diversity and Polarization in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1419-1423.	1.1	372
118	Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human Immunology, 2009, 70, 325-330.	1.2	304
119	Chapter 5 Expression of Chemokines and Chemokine Receptors in Human Colon Cancer. Methods in Enzymology, 2009, 460, 105-121.	0.4	85
120	Orchestration of macrophage polarization. Blood, 2009, 114, 3135-3136.	0.6	100
121	Synergyâ€inducing chemokines enhance CCR2 ligand activities on monocytes. European Journal of Immunology, 2009, 39, 1118-1128.	1.6	36
122	Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood, 2009, 113, 5848-5856.	0.6	82
123	Chemoattractant Receptors and Leukocyte Recruitment: More Than Cell Migration. Science Signaling, 2009, 2, pe10.	1.6	5
124	Non-signaling chemokine receptors: Mechanism of action and role in vivo. Journal of Neuroimmunology, 2008, 198, 14-19.	1.1	10
125	Inflammatory Reaction and Implantation: the New Entries PTX3 and D6. Placenta, 2008, 29, 129-134.	0.7	31
126	Chemokine Decoy Receptors: New Players in Reproductive Immunology. Immunological Investigations, 2008, 37, 483-497.	1.0	35

#	Article	IF	CITATIONS
127	Unique Role of Junctional Adhesion Molecule-A in Maintaining Mucosal Homeostasis in Inflammatory Bowel Disease. Gastroenterology, 2008, 135, 173-184.	0.6	210
128	Epicardial fat thickness: Relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 523-530.	1.1	65
129	Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends in Pharmacological Sciences, 2008, 29, 280-286.	4.0	28
130	Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in <i>Mycobacterium tuberculosis</i> infection. Journal of Experimental Medicine, 2008, 205, 2075-2084.	4.2	94
131	Colifagina, a Novel Preparation of 8 Lysed Bacteria Ameliorates Experimental Colitis. International Journal of Immunopathology and Pharmacology, 2008, 21, 401-407.	1.0	8
132	Regulation of D6 chemokine scavenging activity by ligand- and Rab11-dependent surface up-regulation. Blood, 2008, 112, 493-503.	0.6	76
133	Housekeeping by chemokine scavenging. Blood, 2008, 112, 215-216.	0.6	7
134	Infiltration of Tumours by Macrophages and Dendritic Cells: Tumour-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes. Novartis Foundation Symposium, 2008, , 137-148.	1.2	53
135	Chemokines and Bone Remodeling. International Journal of Immunopathology and Pharmacology, 2008, 21, 485-491.	1.0	26
136	Chemokines as Pharmacological Targets. Mini-Reviews in Medicinal Chemistry, 2008, 8, 638-646.	1.1	17
137	Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. European Cytokine Network, 2008, 19, 119-22.	1.1	46
138	Macrophage activation and polarization. Frontiers in Bioscience - Landmark, 2008, 13, 453.	3.0	2,558
139	The MYD88-Independent Pathway Is Not Mobilized in Human Neutrophils Stimulated via TLR4. Journal of Immunology, 2007, 178, 7344-7356.	0.4	102
140	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2319-2324.	3.3	171
141	Cytokines in Liver Health and Disease. , 2007, , 83-93.		2
142	Adenosine A2areceptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. Journal of Leukocyte Biology, 2007, 82, 392-402.	1,5	69
143	Design of Noncompetitive Interleukin-8 Inhibitors Acting on CXCR1 and CXCR2. Journal of Medicinal Chemistry, 2007, 50, 3984-4002.	2.9	86
144	Targeting tumour-associated macrophages. Expert Opinion on Therapeutic Targets, 2007, 11, 1219-1229.	1.5	56

#	Article	IF	Citations
145	New vistas on macrophage differentiation and activation. European Journal of Immunology, 2007, 37, 14-16.	1.6	355
146	Regulatory pathways in inflammation. Autoimmunity Reviews, 2007, 7, 8-11.	2.5	29
147	Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression. Journal of Immunology, 2006, 177, 7303-7311.	0.4	2,062
148	D6 as a Decoy and Scavenger Receptor for Inflammatory CC Chemokines in the Skin. Handbook of Systemic Autoimmune Diseases, 2006, , 23-28.	0.1	1
149	Migration of dendritic cells across blood and lymphatic endothelial barriers. Thrombosis and Haemostasis, 2006, 95, 22-28.	1.8	20
150	The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses. Biochemical Society Transactions, 2006, 34, 1014-1017.	1.6	11
151	Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nature Reviews Immunology, 2006, 6, 907-918.	10.6	436
152	Selective Modulation of Protein Kinase A I and II Reveals Distinct Roles in Thyroid Cell Gene Expression and Growth. Molecular Endocrinology, 2006, 20, 3196-3211.	3.7	38
153	Differential regulation of chemokine production by Fc receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). Journal of Leukocyte Biology, 2006, 80, 342-349.	1.5	131
154	Migration of dendritic cells across blood and lymphatic endothelial barriers. Thrombosis and Haemostasis, 2006, 95, 22-8.	1.8	5
155	Chemokines and Their Receptors. Pathology Patterns Reviews, 2005, 123, S82-S95.	0.4	11
156	Increased inflammation in mice deficient for the chemokine decoy receptor D6. European Journal of Immunology, 2005, 35, 1342-1346.	1.6	131
157	Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells. Journal of Immunology, 2005, 174, 6561-6562.	0.4	249
158	Transcriptional Profiling Reveals Complex Regulation of the Monocyte IL- $1\hat{l}^2$ System by IL-13. Journal of Immunology, 2005, 174, 834-845.	0.4	132
159	Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Experimental Cell Research, 2005, 310, 176-185.	1.2	48
160	2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4312-4331.	2.9	115
161	Macrophage Polarization Comes of Age. Immunity, 2005, 23, 344-346.	6.6	1,035
162	Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine and Growth Factor Reviews, 2005, 16, 679-686.	3.2	102

#	Article	IF	Citations
163	Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor. Journal of Immunology, 2004, 172, 4972-4976.	0.4	132
164	Distinct Transcriptional Programs Activated by Interleukin-10 with or without Lipopolysaccharide in Dendritic Cells: Induction of the B Cell-Activating Chemokine, CXC Chemokine Ligand 13. Journal of Immunology, 2004, 172, 7031-7042.	0.4	113
165	l̂ ² -Arrestin-dependent Constitutive Internalization of the Human Chemokine Decoy Receptor D6. Journal of Biological Chemistry, 2004, 279, 25590-25597.	1.6	140
166	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11791-11796.	3.3	310
167	Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. Journal of Leukocyte Biology, 2004, 75, 738-742.	1.5	61
168	Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Seminars in Cancer Biology, 2004, 14, 155-160.	4.3	174
169	IL-8 induces a specific transcriptional profile in human neutrophils: synergism with LPS for IL-1 production. European Journal of Immunology, 2004, 34, 2286-2292.	1.6	30
170	Gene expression profile activated by the chemokine CCL5/RANTES in human neuronal cells. Journal of Neuroscience Research, 2004, 78, 371-382.	1.3	42
171	The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology, 2004, 25, 677-686.	2.9	5,272
172	Tuning of Innate Immunity and Polarized Responses by Decoy Receptors. International Archives of Allergy and Immunology, 2003, 132, 109-115.	0.9	30
173	Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6. Journal of Immunology, 2003, 170, 2279-2282.	0.4	181
174	Reduced Cell Surface Expression of CCR5 in CCR5î"32 Heterozygotes Is Mediated by Gene Dosage, Rather Than by Receptor Sequestration. Journal of Biological Chemistry, 2002, 277, 2287-2301.	1.6	65
175	Analysis of the Gene Expression Profile Activated by the CC Chemokine Ligand 5/RANTES and by Lipopolysaccharide in Human Monocytes. Journal of Immunology, 2002, 168, 3557-3562.	0.4	164
176	Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 2002, 23, 549-555.	2.9	4,494
177	The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 972-982.	2.7	65
178	Regulation of the Chemokine System at the Level of Chemokine Receptor Expression and Signaling Activity. Immunobiology, 2001, 204, 536-542.	0.8	11
179	Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends in Immunology, 2001, 22, 328-336.	2.9	332
180	Selective induction of phospholipase D1 in pathogen-activated human monocytes. Biochemical Journal, 2001, 358, 119.	1.7	13

#	Article	IF	CITATIONS
181	Selective induction of phospholipase D1 in pathogen-activated human monocytes. Biochemical Journal, 2001, 358, 119-125.	1.7	19
182	A Membrane-proximal Basic Domain and Cysteine Cluster in the C-terminal Tail of CCR5 Constitute a Bipartite Motif Critical for Cell Surface Expression. Journal of Biological Chemistry, 2001, 276, 40133-40145.	1.6	53
183	The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunological Reviews, 2000, 177, 141-149.	2.8	139
184	Shaping and tuning of the chemokine system by regulation of receptor expression and signaling:. Journal of Neuroimmunology, 2000, 107, 174-177.	1.1	7
185	Induction of Functional IL-8 Receptors by IL-4 and IL-13 in Human Monocytes. Journal of Immunology, 2000, 164, 3862-3869.	0.4	128
186	CHEMOKINES AND CHEMOKINE RECEPTORS: Biology and Clinical Relevance in Inflammation and AIDS. Annual Review of Medicine, 1999, 50, 425-440.	5.0	272
187	Trafficking to the Plasma Membrane of the Seven-Transmembrane Protein Encoded by Human Herpesvirus 6 U51 Gene Involves a Cell-Specific Function Present in T Lymphocytes. Journal of Virology, 1999, 73, 325-333.	1.5	39
188	Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes. Journal of Experimental Medicine, 1998, 187, 439-444.	4.2	230
189	Identification of CCR8: A Human Monocyte and Thymus Receptor for the CC Chemokine I-309. Journal of Experimental Medicine, 1997, 186, 165-170.	4.2	213
190	HIV-1 Coreceptor Activity of CCR5 and Its Inhibition by Chemokines: Independence from G Protein Signaling and Importance of Coreceptor Downmodulation. Virology, 1997, 234, 340-348.	1.1	204
191	The Chemokine Superfamily: Crosstalk with the IL-1 System. Immunobiology, 1996, 195, 522-549.	0.8	15
192	lL- $1\hat{l}^2$ primes lL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. Journal of Leukocyte Biology, 1996, 59, 427-434.	1.5	54
193	Chemokines: a superfamily of chemotactic cytokines. International Journal of Clinical and Laboratory Research, 1996, 26, 69-82.	1.0	90
194	Inhibition of Monocyte Chemotaxis to C-C Chemokines by Antisense Oligonucleotide for Cytosolic Phospholipase A2. Journal of Biological Chemistry, 1996, 271, 6010-6016.	1.6	63
195	Receptors, signal transduction, and spectrum of action of monocyte chemotactic protein-1 and related chemokines. Journal of Leukocyte Biology, 1995, 57, 788-794.	1.5	86
196	Synergism Between Platelet Activating Factor and C-C Chemokines for Arachidonate Release in Human Monocytes. Biochemical and Biophysical Research Communications, 1994, 199, 761-766.	1.0	40
197	Monocyte Chemotactic Protein-1 (MCP-1): Signal Transduction and Involvement in the Regulation of Macrophage Traffic in Normal and Neoplastic Tissues. Advances in Experimental Medicine and Biology, 1993, 351, 47-54.	0.8	24